Latest Annual Report
Filed: 2026-03-31
Key Insights
- The company's research and development expenses have increased year-over-year, indicating continued investment in its drug pipeline.
- Cocrystal Pharma has raised additional capital through an at-the-market offering and a securities purchase agreement, bolstering its financial position.
- The company has made progress in its clinical trials, with a Phase 1B trial for one of its drug candidates ongoing and plans for a Phase 2A trial.